ZDHHC9 and neoplasm: This comprehensive understanding significantly strengthens the rationale for ZDHHC9 as a novel target for BC treatment and supports its prognostic value in identifying patients who might benefit from therapies counteracting tumor palmitoylation-dependent pathways (30).